Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: A longitudinal observational study
| dc.rights.license | open | en_US |
| dc.contributor.author | ALKHAMI, Fadi | |
| dc.contributor.author | BORDERIE, Gauthier | |
| dc.contributor.author | FOUSSARD, Ninon | |
| dc.contributor.author | LARROUMET, Alice | |
| dc.contributor.author | BLANCO, Laurence | |
| dc.contributor.author | BARBET-MASSIN, Marie-Amelie | |
| dc.contributor.author | FERRIERE, Amandine | |
| dc.contributor.author | DUCOS, Claire | |
| dc.contributor.author | MOHAMMEDI, Kamel | |
| dc.contributor.author | FAWAZ, Sami | |
| dc.contributor.author | COUFFINHAL, Thierry | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | RIGALLEAU, Vincent
IDREF: 069788146 | |
| dc.date.accessioned | 2024-03-14T10:30:20Z | |
| dc.date.available | 2024-03-14T10:30:20Z | |
| dc.date.issued | 2024-02-11 | |
| dc.identifier.issn | 1878-1780 (Electronic) 1262-3636 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/188797 | |
| dc.description.abstractEn | BACKGROUND: Cardiovascular disease is frequent in type 2 diabetes mellitus (T2DM). We investigated the relationship between skin autofluorescence (SAF) of advanced glycation end-products and later cardiovascular events (CVEs) in patients with T2DM. RESEARCH DESIGN AND METHODS: We conducted a retrospective analysis of 504 patients hospitalized for uncontrolled and/or complicated T2DM between 2009 and 2017. SAF was measured using an AGE-Reader. Participants were followed up from admission to December 2020, for the onset of a CVE (myocardial infarction, stroke, revascularization procedures or cardiovascular death). The relationship between SAF and CVE was analyzed by multivariable Cox regression. Log-rank curves were used to compare CVE-free survival in patients whose SAF at admission was above versus below the whole-population median. The analysis was repeated in subjects without/with macroangiopathy (defined as myocardial infarction, stroke, peripheral revascularization) at baseline. FINDINGS: During 54 months of follow-up, 69 (13.7%) patients had a CVE. Baseline SAF was significantly higher in patients with T2DM who later experienced a CVE (2.89 ± 0.70 arbitrary units versus 2.64 ± 0.62 in others, P = 0.002). This relationship was significant after adjusting for age, sex, conventional risk factors (diabetes duration, HbA1c, arterial hypertension, dyslipidemia, smoking, body mass index), vascular complications, C-reactive protein, and treatments for diabetes. The CVE-free survival curves differed between subjects whose SAF was above the whole-population median (log-rank: P = 0.002) and those whose SAF was above the macroangiopathy-free sub-population median (log-rank: P = 0.016). CONCLUSION: SAF of advanced glycation end-products was related to a higher incidence of later CVE in patients with T2DM. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Advanced glycation | |
| dc.subject.en | Cardiovascular events | |
| dc.subject.en | Cardiovascular risk | |
| dc.subject.en | End-products | |
| dc.subject.en | Macroangiopathic complications | |
| dc.subject.en | Microangiopathic complications | |
| dc.subject.en | Skin autofluorescence | |
| dc.subject.en | Type 2 diabetes | |
| dc.title.en | Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: A longitudinal observational study | |
| dc.title.alternative | Diabetes Metab | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.diabet.2024.101524 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38346471 | en_US |
| bordeaux.journal | Diabetes & Metabolism | en_US |
| bordeaux.page | 101524 | en_US |
| bordeaux.volume | 50 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Société Francophone du Diabète | en_US |
| bordeaux.identifier.funderID | European Foundation for the Study of Diabetes | en_US |
| hal.identifier | hal-04504400 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-03-14T10:30:22Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes%20&%20Metabolism&rft.date=2024-02-11&rft.volume=50&rft.issue=2&rft.spage=101524&rft.epage=101524&rft.eissn=1878-1780%20(Electronic)%201262-3636%20(Linking)&rft.issn=1878-1780%20(Electronic)%201262-3636%20(Linking)&rft.au=ALKHAMI,%20Fadi&BORDERIE,%20Gauthier&FOUSSARD,%20Ninon&LARROUMET,%20Alice&BLANCO,%20Laurence&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||